Haier Blood Technology Chongqing Co., Ltd.

Haier Blood Technology Chongqing Co., Ltd., formerly a school-run enterprise of the Third Military Medical University of the Chinese People's Liberation Army, was established in 2001. It holds qualifications for the research and development, production, and sales of Class II and Class III medical devices and large-volume injections and other devices and drugs, and is one of the enterprises that simultaneously possesses production qualifications for plasma collection equipment, its supporting consumables, and pharmaceuticals. In October 2020, Haier Biomedical, a STAR Market-listed company under Haier Group, spent 550 million yuan to acquire 90% of the shares of the former Chongqing Sanda Weiye Pharmaceutical Co., Ltd., becoming an important part of Haier Biomedical's layout of the industrial ecosystem for blood safety scenarios, with the company's average annual growth rate reaching 30%. In order to break foreign technological monopolies and build the * blood component safety management solution ecological brand — "Haier Blood Technology", the company invested 230 million yuan to build the Haier Blood Safety Industrial Park. The project covers an area of 78 mu, with a building area of 36,500 square meters. It is a key project of the Chongqing Municipal Development and Reform Commission, a key enterprise and key project of the Municipal Drug Administration. After completion, the full-production output value will reach 1 billion yuan, and it will develop from a single plasma collection solution into a provider of multi-scenario ecological solutions for blood component collection, separation, storage, and more. At the same time, the company leverages the resource advantages of Haier Biomedical to actively explore overseas markets. The company's apheresis plasma consumable products have obtained the domestic industry's * EU MDR certification certificate. The company has successively obtained the Drug GMP Certificate and the Integration of Informatization and Industrialization Management System Assessment Certificate (Grade A), passed the ISO13485 system certification, and is a * high-tech enterprise, a national "specialized, refined, distinctive, and innovative" little giant enterprise, a national intellectual property advantage enterprise, a municipal-level small and medium-sized enterprise technology research and development center, a municipal-level enterprise technology center, a key laboratory, and a Chongqing technological innovation demonstration enterprise. At present, it has 40 valid patents, including 4 invention patents, 29 utility model patents, 5 design patents, and 2 software copyrights; it has medical device registration certificates for blood bags of various specifications and 27 registration approvals for blood safety and other products. Among them, the domestically pioneered Internet of Things leukocyte-reduction blood bag independently developed by the company marks a breakthrough in ecological transformation for smart blood use scenario solutions, forming a full-scenario service system covering blood stations, blood centers, hospitals, and more. The company will continue to increase research and development. Centering on "blood component safety management" and taking the creation of an ecological brand for blood component safety management as its mission, it will strengthen school-enterprise cooperation in aspects such as blood component apheresis, blood storage and transfer, and blood therapy, build a medical-engineering platform, carry out technological breakthroughs, and innovatively promote the intelligentization, automation, IoT connectivity, and platformization of blood component safety management, striving to develop from a comprehensive apheresis plasma solution into a full-scenario ecological brand for blood.